肾上腺素髓质素可诱发无先兆偏头痛发作:随机交叉研究
一项安慰剂对照双盲随机交叉研究纳入20例无先兆偏头痛患者,比较静脉输注人肾上腺素髓质素(19.9 pmol/kg/min)与安慰剂后12小时内偏头痛发作率。结果显示肾上腺素髓质素组11例(55%)满足偏头痛发作标准,安慰剂组仅3例(15%),差异有统计学意义(p=0.039),提示肾上腺素髓质素参与偏头痛发病机制。
要点
- 静脉输注肾上腺素髓质素后12小时内偏头痛发作率显著高于安慰剂(55% vs 15%,p=0.039)。
- 肾上腺素髓质素组0-12小时头痛强度曲线下面积显著高于安慰剂(p=0.035)。
- 常见不良事件为面部潮红、热感及心悸(p<0.001),平均动脉压无显著变化(p=0.502)。
核心结论
- 肾上腺素髓质素可能参与偏头痛发病机制,其本身或受体可能成为偏头痛治疗的新靶点。
- 但不能排除肾上腺素髓质素通过经典降钙素基因相关肽受体发挥作用的可能性。
研究设计与样本
- 安慰剂对照双盲随机交叉临床研究,纳入20例无先兆偏头痛患者。
- 患者接受静脉输注人肾上腺素髓质素(19.9 pmol/kg/min)或安慰剂(生理盐水),输注时间20分钟,洗脱期至少7天。
主要发现
- 肾上腺素髓质素组11例(55%)在输注后满足偏头痛发作标准,安慰剂组仅3例(15%),差异有统计学意义(p=0.039)。
- 肾上腺素髓质素组0-12小时头痛强度曲线下面积显著高于安慰剂组(p=0.035)。
- 心率与面部潮红的0-90分钟曲线下面积差异有统计学意义(p<0.05),平均动脉压的0-90分钟曲线下面积无显著变化(p=0.502)。
- 常见不良事件为面部潮红、热感及心悸(p<0.001)。
关键数值与推荐
- 主要结局为0-12小时偏头痛发生率差异,肾上腺素髓质素组55%(11/20) vs 安慰剂组15%(3/20),p=0.039。
- 次要结局包括头痛强度评分0-12小时曲线下面积(p=0.035)、平均动脉压0-90分钟曲线下面积(p=0.502)、面部潮红及心率0-90分钟曲线下面积(p<0.05)。
临床怎么用
- 该研究为机制探索性研究,提示肾上腺素髓质素通路可能作为偏头痛治疗的新靶点,但尚未提供临床治疗推荐。
局限性
- 样本量较小(20例无先兆偏头痛患者),结果需在更大样本中验证。
- 不能排除肾上腺素髓质素通过经典降钙素基因相关肽受体介导效应的可能性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To determine whether the IV infusion of adrenomedullin, a potent vasodilator belonging to calcitonin family of peptides, provokes attacks of migraine in patients. METHODS: Twenty patients with migraine without aura participated in a placebo-controlled and double-blind clinical study. In a randomized crossover design, the patients received an IV infusion of human adrenomedullin (19.9 pmol/kg/min) or placebo (saline) administrated via an automated IV pump (20 minutes). The patients participated in 2 study days with a washout period of minimum of 7 days. The primary outcome of the study was predefined as a difference in migraine incidence (0-12 hours), and the secondary outcomes were the area under curve (AUC0-12 hours) for the headache intensity score and AUC0-90 minutes for mean arterial blood pressure (MAP), flushing, and heart rate (HR). RESULTS: Eleven patients with migraine without aura (55%) fulfilled migraine attacks criteria after adrenomedullin infusion compared to only 3 patients who reported attack (15%) after placebo (p = 0.039). We found that patients reported in a period of 0 to 12 hours stronger headache intensity after adrenomedullin compared to placebo infusion (p = 0.035). AUC0-90 minutes value for HR and flushing (p < 0.05) was significant and for MAP (p = 0.502) remained unchanged. Common reported adverse events were facial flushing, heat sensation, and palpitation (p < 0.001). CONCLUSION: Our data implicate adrenomedullin in migraine pathogenesis. This suggests that adrenomedullin or its receptors are novel therapeutic targets for the treatment of migraine. However, we cannot discount the possibility that adrenomedullin may be acting through the canonical calcitonin gene-related peptide receptor. TRIAL REGISTRATION INFORMATION: ClinicalTrials.gov Identifier: NCT04111484.
引用
- Ghanizada H, Al-Karagholi MA, Arngrim N, et al. Effect of Adrenomedullin on Migraine-Like Attacks in Patients With Migraine: A Randomized Crossover Study. Neurology. 2021. PMID: 33827963. doi:10.1212/WNL.0000000000011930
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。